Drug Trial Radar · NCT03794180
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Dec 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Mar 18, 2019
Primary completion
Sep 5, 2019
Study completion Sep 5, 2019
Sponsor
- Lead sponsor
- I-Mab Biopharma US LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
TJ003234RAR101 is a first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled, single ascending dose study of TJ003234 in healthy adults to determine whether TJ003234 is safe and tolerated when administered as an intravenous (IV) infusion and to determine the maximum dose tolerated (MTD).
Conditions
- Healthy Adult Subjects
Interventions
TJ003234Drug
Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
PlaceboDrug
Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Profile: AEsTime frame: Up to 85 days after study drug administration
- Maximum Tolerated DoseTime frame: Up to 85 days after study drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.